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Abstract
Endocannabinoids and some phytocannabinoids bind to CB1 and CB2 cannabinoid receptors, transient receptor
potential vanilloid one (TRPV1) receptor and the orphan G protein receptor fifty-five (GPR55). Studies using
C57BL/10 and C57BL/6 (Cnr2tm1Zim) CB2 cannabinoid receptor knockout mice have demonstrated an immune-
augmenting effect in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis. However, other
EAE studies in Biozzi ABH mice often failed to show any treatment effect of either CB2 receptor agonism or
antagonism on inhibition of T cell autoimmunity. The influence of genetic background on the induction of EAE in
endocannabinoid system-related gene knockout mice was examined. It was found that C57BL/6.GPR55 knockout
mice developed less severe disease, notably in female mice, following active induction with myelin oligodendrocyte
glycoprotein 35-55 peptide. In contrast C57BL/6.CB2 (Cnr2Dgen) receptor knockout mice developed augmented
severity of disease consistent with the genetically and pharmacologically-distinct, Cnr2tm1Zim mice. However, when the
knockout gene was bred into the ABH mouse background and EAE induced with spinal cord autoantigens the
immune-enhancing effect of CB2 receptor deletion was lost. Likewise CB1 receptor and transient receptor potential
vanilloid one knockout mice on the ABH background demonstrated no alteration in immune-susceptibility, in terms of
disease incidence and severity of EAE, in contrast to that reported in some C57BL/6 mouse studies. Furthermore the
immune-modulating influence of GPR55 was marginal on the ABH mouse background. Whilst sedative doses of
tetrahydrocannabinol could induce immunosuppression, this was associated with a CB1 receptor rather than a CB2
receptor-mediated effect. These data support the fact that non-psychoactive doses of medicinal cannabis have a
marginal influence on the immune response in MS. Importantly, it adds a note of caution for the translational value of
some transgenic/gene knockout and other studies on low-EAE susceptibility backgrounds with inconsistent disease
course and susceptibility.
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Introduction
Multiple sclerosis (MS) is an immune-mediated,
demyelinating disease of the central nervous system. This
results in the development of troublesome symptoms, some of
which respond to treatment with cannabis [1]. The
endocannabinoid system consists of CB1 and CB2 cannabinoid
receptors and a number of endocannabinoid ligands and their
synthetic and degradation molecules. However,
endocannabinoids and phytocannabinoids may stimulate other
receptors such as transient receptor potential vanilloid one
(TRPV1) ion channel and the orphan G protein coupled
receptor 55 (GPR55) [2-5]. There is increasing evidence that
Δ9-tetrahydrocannabinol (THC. A CB1 and CB2 receptor agonist
[2]) within cannabis and the CB1 receptor can regulate aberrant
synaptic neurotransmission and control symptoms such as
spasticity, which are associated with nerve damage in MS
[1,2,6]. Pharmacological control of spasticity translated from
experimental autoimmune encephalomyelitis (EAE) model in
rodents to the treatment of MS in humans [1,7,8]. However, the
distribution of CB1 receptors on nerves and CB2 receptors on
immune cells [2] suggest that cannabinoids may have
additional influences on MS. As such there is increasing
evidence to indicate that cannabinoids may control
neurodegenerative mechanisms [9,10]. There is also much
interest on whether cannabinoids may influence (auto)immune
aspects of MS that may drive relapsing disease.
There are no cannabinoid receptor ligands that have total
receptor specificity; rather all have varying degrees of receptor
selectivity [11]. In vitro assays allow dose-titration and off-target
effects to be minimised, but in vivo this may be more complex
where high doses may be administered to get adequate
receptor coverage over time. However, depending on the
bioavailability and route of administration there may be high
peaks of compound concentration and drug metabolism has
the potential of creating new active molecules. Both of these
factors increase the chance of off-target effects. Whilst target
validation is often achieved by use of pharmacological
antagonists, these too have off-target effects [11]. Thus,
specific gene deletion or gene silencing provides an extra level
of precision in determining target validity [6]. The influence of
cannabinoid receptor deletion in the initial acute phase of
disease models of MS has been reported previously for CB1
receptor [9,10,12], CB2 receptor [12,13] and TRPV1 gene
knockout mice [14]. The influence of GPR55 on EAE is
however unknown. GPR55 is expressed at low levels in a
variety of tissues that include blood vessels and nervous tissue
and immune tissues. However, the function of GPR55 is poorly
defined [3-5]. This study examined the influence of GPR55
gene knockout on susceptibility to EAE.
Initial studies in EAE using central nervous system myelin
and myelin basic protein indicated that susceptibility was
polygenic with an important influence of major
histocompatibility complex (MHC) haplotype. It was found that
C57BL/6 and 129 mice (H-2b) are relatively EAE resistant
compared to highly susceptible strains such as SJL (H-2s) and
Biozzi ABH (H-2dq1) mice [15,16]. However, the demonstration
that myelin oligodendrocyte glycoprotein (MOG) could induce
disease in H-2b mice [17] means that the majority of studies
using transgenic and gene knockout tissue are now performed
in MOG35-55 peptide-induced EAE in C57BL/6 mice. Previously
we have reported that CB2 knockout C57BL/10.Cnr2tm1Zim mice
develop augmented EAE, yet pharmacological agonism and
antagonism of CB2 receptors consistently failed to influence the
development of EAE, when examined in ABH mice [12,18].
Disease in C57BL/6 can be highly variable in terms of timing of
onset, and the disease severity induced [19,20]. Therefore, we
hypothesised that the immune-modulating influence of CB2
deficiency may be lost when studies are performed in strains
that are fully susceptible to EAE induction. The influence of
cannabinoid gene deletion on an EAE susceptible background
was examined and demonstrated that they have a limited
immune phenotype, which affects susceptibility to disease
induction.
Materials and Methods
Ethics Statement
All animal studies were approved by the Queen Mary
University Ethical Review panel and the United Kingdom
Government Home Office Inspectorate. These studies where
performed under Licence from the UK Home Office and
conformed to the United Kingdom Animals (Scientific
Procedures) Act 1986 for the use of animals in research.
Animals
Mice were from in-house bred stock that was maintained in a
12h light/dark cycle with controlled humidity and temperature
and animals were fed RM-1E diet and water ad libitum. These
were housed as described previously, to conform with the
ARRIVE guidelines [21]. Biozzi ABH and congenic
ABH.Cnr1tm1Par mice CB1 receptor knockout mice [9] were from
stock bred at Queen Mary University of London. 129 mice were
purchased from Charles Rivers, Margate, UK. Male B6.129P2-
Cnr2tm1Dgen/J homozygous CB2 receptor knockout mice [22]
were purchased from Jackson Laboratories (Bar Harbor, Maine
USA). These mice had been backcrossed onto the C57BL/6/J
background for more than 5 generations at the time of arrival.
These were backcrossed with C57BL/6/J (Charles Rivers
Margate, Kent) and then intercrossed to produce C57BL/
6.Cnr2tm1Dgen CB2 receptor knockout mice. In addition, mice
were backcrossed with ABH mice for more than 11
generations, screening for CB2 receptor expression at each
generation, prior to intercross to produce congenic
ABH.Cnr2tm1Dgen mice. C57BL/6.Trpv1tm1Jbd, TRPV1 knockout
mice [23] were obtained from Dr. John B Davis, Glaxo Smith
Kline, Stevenage, UK. These were backcrossed with ABH mice
for 6 generations and screened for the expression of the
neomycin resistance gene [9] within the targeting expression
cassette at each generation, prior to intercross to produce
ABH.Trpv1tm1Jbd mice. Functional knockout of the gene was
demonstrated following the lack visible sedation and lack of
hypothermia (>1°C body temperature loss within 20min
following injection i.v. of 0.5mg/kg arvanil in measured with a
thermocouple as described previously [21]). Loss of receptor
expression was confirmed by TRPV1-specific
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immunocytochemistry [24]. Founder B6.129-Gpr55tm1Tigm
GPR55 knockout mice were purchased from the Texas Institute
of Genomic Medicine (College Station, Texas, USA). This
mouse lacks the entire coding sequence as described [25].
These were caesarean re-derived and backcrossed twice with
C57BL/6/J mice. Then heterozygous animals were crossed
with either a heterozygous or homozygous mouse to produce
C57BL/6.Gpr55-/-. In addition mice were backcrossed with
ABH mice for over 11 generations to produce ABH.Gpr55tm1Tigm
mice and following intercross ABH.Gpr55-/- were generated.
Wildtype C57BL/6/J and C57BL/6.Cnr1tm1Zim CB1 receptor
knockout mice [26], C57BL/6.Cnr2tm1ZimCB2 receptor knockout
mice [27] were obtained from Dr. George Kunos, National
Institutes of Health, Bethesda, Maryland, USA, C57BL/
6.Cnr2tm1Dgen CB2 receptor knockout mice and C57BL/
6.Gpr55tm1Tigm GPR55 knockout mice derived from the stock
above were bred in individual ventilated cages at the University
of Aberdeen.
Chemicals
Arvanil (N-Vanillylarachidonamide) was purchased from
Cayman Chemical (AnnHarbor, Michigan, USA). R(+) WIN55
212-2 (WIN55.(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenylmethanone mesylate) was purchased from Tocris,
Bristol, UK. Δ9Tetrahydrocannabinol (THC) was purchased
from THC pharm, Frankfurt, Germany. A selective GPPR55
ligand (R)3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-
methyl-ethyl) benzamide was synthesised as described
previously [28]. 2007). WIN55 was dissolved in dimethyl
sulphoxide:cremaphor:phosphate buffered saline (PBS) 1:1:18.
These were purchased from Sigma (Poole, Dorset, UK).
Arvanil and THC were dissolved in ethanol:cremophor:PBS
(1:1:18). These were administered via the intravenous route,
for screening purposes, or daily via the intraperitoneal routes in
0.1ml.
Genotyping
Genotyping was performed as described previously [9]
Briefly ear biopsies were removed from weaned mice and DNA
samples were prepared following digestion overnight at 60°C in
500 μl 0.2g/ml Proteinase K (Invitrogen, Paisley, UK) in
Nucleon TM Reagent B lysis buffer pH8 (400mM Tris/HCl,
60mM EDTA, NaCl 150mM, 1 % sodium dodecyl sulphate).
150μl 5M sodium perchlorate was added followed by a further
30 minute incubation at 60°C. Equal volumes of chloroform
were added, the sample vortexed and centrifuged for 4 minutes
at 14000rpm in an Eppendorf microfuge. The aqueous phase
was added to 2 volumes of cold ethanol to precipitate the DNA,
which was then dissolved in water. DNA was amplified using
polymerase chain reaction using Qiagen PCR core kit reagents
(Qiagen, Crawley, UK) as described previously [9]. Samples
were amplified using 35 cycles 94°C 60s, 55 or 60°C 60s, 72°C
60s) with Cnr2 primers (Annealing temperature 60°C, Forward
5’GGGGATCGATCCGTCCTGTAAGTCT3’, Reverse1
5’GGAGTTCAACCCCATGAAGGAGTAC3’, Reverse2
5’GACTAGAGCTTTGTAAGGTAGGC3’. Size of products:
wildtype 350 base pairs, transgene 500 base pairs) and Gpr55
primers (Annealing temperature 55°C, Forward
5’TCTGGATTCATCGACTGTG3’, Reverse1
5’TCCACAATCAAGCTG3’, Reverse 2.
5’GTCACCCATCCAGGTGAT3’. Size of product: wildtype 207
base pairs and transgene 299 base pairs). Products were
identified by gel electrophoresis using 2% agarose in Tris
borate EDTA buffer (Sigma) gels
CB2 receptor Binding Assays
The binding affinity of compounds was performed by contract
research organisations on stably human CNR2 transfected cell
lines using cyclic AMP assays (Multispan Inc. Hayward,
California, USA) or GTPγS binding assay (MDS pharma.
Taipei, Taiwan).
Vas Deferens Assay
Vasa deferentia were obtained from mice weighing 30 to 50
g. Each tissue was mounted in a 4 ml organ bath at an initial
tension of 0.5g. The baths contained Mg2+-free Krebs solution
which was kept at 35°C and bubbled with 95% O2 and 5% CO2.
The composition of the Krebs solution was (mM): NaCl 118.2,
KCl 4.75, KH2PO4 1.19, NaHCO3 25.0, glucose 11.0 and
CaCl2 .6H2O 2.54. Isometric contractions were evoked by
stimulation with 0.5s trains of three pulses of 110% maximal
voltage (train frequency 0.1Hz; pulse duration 0.5ms) through a
platinum electrode attached to the upper end and a stainless
steel electrode attached to the lower end of each bath. Stimuli
were generated by a Grass S48 stimulator, then amplified
(Med-Lab channel attenuator) and divided to yield separate
outputs to four organ baths (Med-Lab StimuSplitter).
Contractions were monitored by computer using a data
recording and analysis system (MacLab) that was linked via
preamplifiers (Macbridge) to UF1 transducers. After placement
in an organ bath, each tissue was subjected to a stimulation-
free period of 15 min and then stimulated for 10 min. Tissues
were then subjected to alternate periods of stimulation (5 min)
and rest (10 min) until consistent twitch amplitudes were
obtained. This equilibration procedure was followed by a
stimulation-free period of 30 min. Tissues were then stimulated
for 10 min after which the stimulator was switched off and (R)3-
(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-
ethyl)benzamide or its vehicle added. Additions of the
compounds were made cumulatively at 15 min intervals without
washout, the tissues being stimulated for the final two minutes
of exposure to each concentration of this agonist. Compounds
were dissolved in DMSO at 10mM and diluted in saline. By
themselves, these vehicles did not inhibit the twitch response.
Drug additions were made in a volume of 10 µl. R(+)
WIN55,212 served as a positive control. The degree of
inhibition of evoked contractions induced by agonist was
calculated in percentage terms by comparing the amplitude of
the twitch response after each addition of agonist with its
amplitude immediately before the first addition of this agonist
[29].
Genetic Background Influences EAE Susceptibility
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e76907
Induction of Experimental Autoimmune
Encephalomyelitis
ABH mice and ABH congenic mice were injected with 1mg of
freeze dried spinal cord homogenate in Freunds adjuvant in the
flank on day 0 and 7 as described previously [21]. C57BL/6
wildtype and C57BL/6-transgenic mice were injected with
200µg mouse MOG35-55 peptide in Freunds adjuvant
supplemented with 400µg/mouse Mycobacterium tuberculosis
H37Ra on day 0 and day 7. These were also injected i.p. with
200ng Bordetella pertussis toxin (Sigma) in phosphate buffered
saline at the time of administration of the Freunds adjuvant and
this was repeated after 24h as described previously [21,30].
Randomisation for allocation to groups, sample size
calculations, blinding and other aspects of experimental design
and reporting consistent with the ARRIVE guidelines have
been described previously [21]. Disease was monitored and
scored 0=normal, 1=limp tail, 2=impaired righting reflex, 3=
paresis of the hind limbs, 4=hind limb paralysis, 5= moribund
(endpoint)/death with 0.5 less than the indicated grade for
milder signs as described previously [21]. The data is
presented as the mean daily clinical score ±standard error of
the mean (SEM) or the mean maximal clinical score of the
group (Group Score) ±SEM; the mean maximal clinical score of
the animals that developed clinical disease (EAE Score) ±SEM
and the mean day of onset ± standard deviation (SD).
Differences between groups, including disease incidence, were
assessed using non-parametric, Mann Whitney U statistics
using Sigmastat/Sigmaplot Software (Systat Chicago, Illinois,
USA).
Immunophenotyping
Mice were killed by CO2 overdose or by cervical dislocation
and lymphocytes from blood and spleen were collected under
sterile conditions. Large spleen fragments were initially
removed by passing the cell suspension though a nylon mesh
on a 50 ml falcon tube and the cells were recovered by
centrifugation for 5 min at 478g. Erythrocytes from the spleen
cell suspension and from the blood were then lysed with a
hypotonic ammonium chloride red blood cell lysis buffer
(eBioscience Ltd, Hatfield, UK) for 5 min at room temperature.
100μl of 2x106 cells/ml in staining buffer (1xPBS, 2% foetal calf
serum) were incubated with various antibodies to surface
antigens (CD3, CD4, CD8, CD19, CD11c, CD25, CD45 and
F4/80) and intracellular cytokines (IL-2, IL-4, IL-10, IL-17A and
IFN-γ) (BD bioscience, Oxford, UK). Antibodies were diluted
1:100 and incubation conducted for 30 min in the dark at 4°C or
on ice. A transcription factor FOX3P was also used to identify
regulatory T cells. After incubation, 3ml of staining buffer was
added to each tube. Tubes were then centrifuged at 478g 5
min at 4°C. After centrifugation pellets were resuspended in
300μl of staining buffer. Cells were analysed using flow
cytometry.
The production of cytokines were supported using
quantitative polymerase chain reaction to detect IL-2 Forward
5’GCATGTTCTGGATTTGACTC3’ and reverse
5’CAGTTGCTGACTCATCATCG3; IL-4 Forward
5’CAAACGTCCTCACAGCAACG3’ and reverse
5’CTTGGACTCATTCATGGTGC3’; IL-10 Forward
5’GGTTGCCAAGCCTTATCGGA3’ and reverse
5’ACCTGCTCCACTGCCTTGCT3’; IL-17A
Forward5’AGCGTGTCCAAACACTGAGG3’ and reverse
5’CTATCAGGGTCTTCATTGCG3’; Interferon gamma
Forward5’CCATCAGCAACAACATAAGC3’ and reverse
5’AGCTCATTGAATGCTTGGCG3’; and beta actin Forward
5’AATCGTGCGTGACATCAAAG3’ and reverse
5’ATGCCACAGGATTCCATACC3’. Quantitative PCR was
performed in duplicates in 96-well reaction plates with the
Applied Biosystems 7500 Real-Time PCR system (Applied
Biosystems, Warrington, Cheshire, UK) and the cycling
conditions for the qPCR were as follows: 95°C (15 min), 40
cycles of 94°C for (45 s), 58°C for (45 s), 72°C (40s).
Lymphocytes were collected on day 9 and re-stimulated in
vitro with MOG peptide at concentrations 1μg/ml or 10μg/ml for
72h. Lymphocytes from naïve GPR55 knockout and wildtype
mice were also collected and stimulated with 5μg/ml
concanavalin A for 48h. A total of 300,000 cells were then
resuspended in a final volume of 100μl of RPMI, 10% FCS and
plated in 96 well-plates. A total of 0.5 units of 3H thymidine
(PerkinElmer LAS, Beaconsfield, Bucks, UK) was added to
each well and cells were incubated during for 24h at 37°C in
5%CO2. Cells were then harvested (Mach III M cell harvester
96, Tomtec, Warwick UK) and analysed on a counter (Wallac
1450, Microbeta plus Liquid Scintillation Counter,
Cambridgeshire, UK). In some instances proliferation was
assessed using 5μM carboxyfluorescein diacetate, succinimidyl
ester (Invitrogen, Paisley, UK), which was incubated with cells
at 37°C for 10 minutes. One volume of ice-cold foetal calf
serum (FCS) was then added to quench the staining and cells
were then washed twice in staining buffer (1x PBS 2% FCS)
and then incubated for 4 days. Samples were analysed by flow
cytometry.
Results
GPR55 deficient C57BL/6 mice have an
immunophenotype in female mice
Founder mice with the Gpr55tm1Tigm transgene that deletes the
entire coding region of Gpr55 were obtained and backcrossed
onto the C57BL/6 background. Following immunization of mice
with MOG35-55 peptide in Freunds adjuvant, it was found that
GPR55-deficient mice developed significantly (P<0.05) lower
severity disease compared to their littermates (Figure 1. Table
1A). As males were being used for analysis in vas deferens
assays female animals were used. Therefore, it was of interest
when further analysis of additional GPR55-deficient mice was
undertaken the data indicated that female mice were notably
more resistant to EAE induction than male mice. Only 2/8
female Gpr55-/- mice developing EAE with a group score 1.0 ±
0.7 compared with 11/12 wildtype littermates developing EAE
with a score of 2.9 ± 0.4 (P<0.05). (Table 1B) Disease in male
GPR55 knockout mice was not significantly different from
wildtype littermates with a group score 2.5 ± 0.8 compared to
3.0 ± 0.5 in littermates. These mice did not relapse or develop
spasticity. These data suggest that there is an immune
phenotype in these mice that inhibits the generation of T cell
autoimmunity. There was however, no apparent differences in
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the number of CD4+, CD8+, CD19+, CD11c+, F4/80+ and
CD4+, Fox3P+, CD25+ regulatory cells in the thymus, spleen
and blood (n=5/group) of male and female C57BL/6.Gpr55-/-
and wildtype mice assessed using flow cytometry. Furthermore
there were no differences in their mitogenic T cell responses to
5µg concanavalin A in male or female mice (Figure S1A). Mice
failed to give specific-proliferative responses to MOG35-55 in
vitro even after immunization (Figure S1B), because there was
a high endogenous proliferation in splenocytes from animals
injected with MOG35-55 peptide in Freunds adjuvant and
pertussis toxin (Figure S2). No specific proliferation was
detected irrespective of GPR55 genotype in male or female
(Figure S2). There were no differences in gamma interferon,
IL-4, IL-10 or IL-17 levels (data not shown).
CB2 receptor-deficient mice develop an augmented
immune response on the C57BL/6 but not ABH mouse
background.
As C57BL/6.GPR55 knockout mice, as shown here, and
C57BL background CB2 (Cnr2tm1Zim) knockout mice reported
previously [12,13] show differences in EAE susceptibility, the
following data prompted us also to reinvestigate the influence
of CB2 receptor deletion on EAE. One of first compounds that
was reported to stimulate GPR55 was (R) 3-(5-
dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)
benzamide [28]. This could potently inhibit electrically induced,
autonomic nerve-induced activity in the vas deferens (Figure
S3). In contrast to effects in wildtype mice its efficacy was
markedly absent when tested in the vas deferens assay from
GPR55 knockout mice. This supported an effect of the
compound at GPR55. The potent inhibition of contraction in
wildtype mice (EC50 = 10.4nM) was essentially unaltered in CB1
Figure 1.  GPR55-deficiency can inhibit the development of EAE in C57BL/6 mice.  Female C57BL/6 GPR55 knockout (n=10
white circles) and heterozygous wildtype littermates (n=5. Filled grey circles) were injected with 200μg MOG35-55 peptide in Freunds
adjuvant on day 0 and 7. Neurological signs were scored daily 0-5 scale. The results represent the mean ± SEM daily scores (Table
1A).
doi: 10.1371/journal.pone.0076907.g001
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 receptor (Cnr1tm1Zim) knockout mice (EC50 = 12.7nM). Likewise
there was essentially no inhibitory effect in C57BL/6.Cnr2tm1Dgen,
CB2 receptor knockout mice (EC50 = 17.6 nM). In contrast, the
activity of (R) 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-
hydroxy-1-methyl-ethyl) benzamide was markedly attenuated in
C57BL/6.Cnr2tm1Zim mice with a EC50 = 249.7nM (Figure S3).
This was surprising as 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-
(2-hydroxy-1-methyl-ethyl)benzamide does not appear to bind
to CB2 receptors, tested to 10µM, in stably transfected
HEK293T.CNR2 and CHO-K1,CNR2cells using cAMP assays
(CP55,940 EC50=1nM) or GTPγS binding assays (CP55,940
EC50=2.37nM, WIN-55 EC50=2.37nM). This indicates that the
two different CB2 receptor knockout mouse strains do not
respond identically to pharmacological treatments and one may
possibly have a defect in GPR55 function in addition to a
functional silencing of CB2 receptor. Therefore, further EAE
studies in C57BL/6.Cnr2tm1Zim mice were terminated.
New experiments were initiated in C57BL/6.Cnr2tm1Dgen CB2
receptor knockout mice to determine whether they would
respond similarly to C57BL/6.Cnr2tm1Zim CB2 receptor knockout
mice. Indeed, it was found that C57BL/6.Cnr2tm1Dgen CB2
receptor knockout developed more severe neurological signs
(P<0.05) compared to wildtype littermates (Figure 2A and
Table 1B, Table 1C). When EAE susceptibility was re-
investigated following the production of fully congenic CB2
receptor deficient ABH mice, it was found that they exhibited a
disease course that was comparable to wildtype ABH mice
(Figure 2B and Table 1D). This lack of apparent influence of
immune activity in ABH.CB2 knockout mice was seen also in
CB1 (ABH.Cnr1tm1Par) receptor (Table 1E, Figure 3A) and
TRPV1 (ABH.Trpv1tm1Dav) knockout mice (Table 1F).
Previously, it has been reported that only doses above
2.5mg/kg THC i.p./day that induce cannabimimetic effects can
induce immunosuppression in ABH mouse EAE [18]. It was
evident that high dose (daily 20mg/kg i.p. Figure 3A or 25mg/kg
i.p. Figure 3B) of THC, which caused visible sedation, could be
immunosuppressive and significantly (P<0.001) inhibited the
development and severity of EAE (Figure 3, Table 2). However,
Table 1. CB1, CB2, TRVP1 and GPR55 gene deletions exhibit minimal impact on the develop of an autoimmune response on
the ABH mouse background compared to C57BL/6 background.
Code  Strain No. EAE  Group Score ± SEM EAE Score ± SEM Day of Onset ± SD
 Initial Acute Disease     
A ♀C57BL/6.Gpr55-/+ 5/5 3.6 ± 0.3 3.6 ± 0.3 13.8 ± 0.8
 ♀C57BL/6.Gpr55-/- 5/10 1.1 ± 0.4** 2.1 ± 0.5* 15.8 ± 1.7*
 ♀C57BL/6.Cnr2+/+ 4/9 0.9 ± 0.5 2.0 ± 0.7 15.3 ± 2.2
 ♀C57BL/6.Cnr2-/- 9/10 3.3 ± 0.4** 3.7 ± 0.2 16.8 ± 0.5*
B ♂C57BL/6.Gpr55+/+ 11/12 3.0 ± 0.5 3.9 ± 0.1 15.3 ± 1.1
 ♂C57BL/6.Gpr55+/+ 4/6 2.5 ± 0.8 3.8 ± 0.8 18.0 ± 1.4*
 ♀C57BL/6.Gpr55-/+ 11/12 2.9 ± 0.4 3.1 ± 0.4 16.2 ± 1.3
 ♀C57BL/6.Gpr55-/- 2/8** 1.0 ± 0.7* 4.0 ± 0.0 15.0 ± 1.9
C ♀C57BL/6.Cnr2+/+ 1/10 0.1 ± 0.1 1.0 ± n/a 17.0 ± n/a
 ♀C57BL/6.Cnr2-/- 6/11 1.3 ± 0.4 2.4 ± 0.3 16.8 ± 1.7
 ♀129 wildtype 9/10 1.0 ± 0.1 1.1 ± 0.1 16.6 ± 0.7
 ♀ABH wildtype 14/18 3.0 ± 0.4 3.8 ± 0.1 16.6 ± 2.2
D ♂♀ABH.Cnr2+/+ 13/13 4.5 ± 0.1 4.5 ± 0.1 15.7 ± 0.8
 ♂♀ABH.Cnr2-/- 12/12 4.2 ± 0.2 4.2 ± 0.2 15.8 ± 1.9
E ♂♀ABH.Cnr1+/+ 6/6 4.0 ± 0.0 4.0 ± 0.0 16.3 ± 1.8
 ♂♀ABH.Cnr1-/- 15/15 4.1 ± 0.1 4.1 ± 0.1 16.3 ± 1.8
F ♂♀ABH.Trpv1+/+ 9/9 3.6 ± 0.1 3.6 ± 0.1 15.4 ± 1.1
 ♂♀ABH.Trpv1-/- 11/11 3.8 ± 0.1 3.8 ± 0.1 16.0 ± 1.0
G ♂ABH.Gpr55+/+ 16/16 3.6 ± 0.1 3.6 ± 0.1 16.6 ± 2.2
 ♂ABH.Gpr55-/- 12/13 3.2 ± 0.3 3.2 ± 0.3 17.1 ± 2.0
 ♀ABH.Gpr55+/+ 12/12 3.8 ± 0.1 3.8 ± 0.1 15.2 ± 1.2
 ♀ABH.Gpr55-/- 21/21 3.1 ± 0.2* 3.1 ± 0.2* 16.6 ± 2.4
 Induced Relapse     
H ♂ABH.Gpr55+/+ 16/16 3.9 ± 0.1 3.9 ± 0.1 34.9 ± 1.4
 ♂ABH.Gpr55-/- 13/13 3.7 ± 0.2 3.7 ± 0.2 34.7 ± 1.4
 ♀ABH.Gpr55+/+ 12/12 3.9 ± 0.1 3.9 ± 0.1 35.4 ± 1.3
 ♀ABH.Gpr55-/- 21/21 3.8 ± 0.1 3.8 ± 0.1 34.8 ± 1.0
Animals were injected with either mouse spinal homogenate in Freunds adjuvant in ABH mice or MOG35-55 peptide in Freunds adjuvant on day 0 and 7and PTX in C57BL/6
background mice. The results show the incidence of EAE, the mean maximal neurological score for the group ± SEM, score of animals that develop clinical EAE ± SEM and
the first day of onset of neurological signs up to day 22 post-inoculation.
* P<0.05, **P<0.01 compared to littermate controls.
doi: 10.1371/journal.pone.0076907.t001
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the immunosuppressive effect did not appear to be CB2
receptor mediated, but was largely a product of CB1 receptor
activity. The immunosuppressive activity was markedly
attenuated in CB1 receptor-deficient mice (Figure 3A) and was
essentially unaltered in CB2 receptor knockout mice following
daily administration of 25mg/kg i.p. (Figure 3B. Table 2). This
further suggests that CB2 receptor agonism may have a weak
potential to modulate robust T cell-driven inflammation.
GPR55 deficient ABH mice have a very modest
immunophenotype in female mice.
These studies indicate that genetic background can influence
the disease course. Therefore, we backcrossed the GPR55
gene deletion for over 11 generations onto the ABH genetic
background to generate fully congenic ABH.Gpr55-/- mice.
Following the induction of EAE in these mice there was a
marginal inhibitory effect on the clinical course in the initial
acute phase of EAE (Figure 4A), with a small but statistically
significant (P<0.05) reduction in the severity of EAE in female
mice (Table 1). There was no influence on disease in male
mice (Figure 4B and Table 1G). However, when a relapse was
induced in these mice there was no inhibitory effect in either
female or males mice (Figure 4C & 4D and Table 1H). This
suggests that antagonism of the GPR55 may offer little as a
means of immunosuppressing disease and was consistent with
the lack of any obvious phenotypic differences following T and
B cell immunophenotying in GPR55-deficient, C57BL/6 mice.
This suggests that genetic background and disease induction
can have major influence on outcome in the prediction of the
influence of transgenesis during EAE.
Discussion
There has been a general failure to translate findings from
animal models into the treatment of many human diseases.
This includes treatments of stroke and multiple sclerosis
[31,32]. Part of the problem is probably due to failings with the
clinical development of agents such as inappropriate trial
design and patient selection. Failure to translate treatments
may relate also to differences in the biology between rodents
and humans or the lack of validity of the animal models.
Importantly, studies in rodents seldom examine
pharmacological agents in a therapeutic context and at a
pharmacological dose relevant to how they will be used
clinically [32]. As such, a therapeutic treatment paradigm in
rodents may consist of treatment for a few days after the
development of first signs compared to the months and years
in humans following development of relapsing disease [32]. It is
has also been noted that reporting and possibly implementation
of elements of experimental design have been poor in animal
studies and that may contribute to the lack of translation
[31-33]. An additional potential problem as highlighted here
could be the use of inbred animals in research. This means
that drugs are being tested in essentially hundreds of the same
individual. This may be a particular problem if the standard tool
has poor consistency and translatability. Although one solution
may be to use outbred mice, this adds to variability and
increases group sizes, which is against the principles of
reduction, refinement and replacement of animals in research.
Therefore, it has been argued that replication in a number of
inbred strains may be useful [34]. Whilst there may be debate
about which animal strains better reflect human disease,
reproduction of findings across a number of strains and species
may increase the translational value. As such, FTY720
consistently inhibits development of EAE across a number of
strains and species [35,36] and formulated FTY720 in the form
of fingolimod inhibits relapsing MS in humans [37].
Myelin peptide-induced disease is useful for the study of T
cell immunology in vitro, but this may not always give the
reproducibility of disease induction as found using tissue
homogenates [16,30]. The disease course in spinal cord
homogenate-induced disease in ABH mice has been consistent
over many years [16,21]. Such reproducibility means that
failure to show high incidence of robust severity and compact
timing of onset is a failure in the quality-control of the
experiment, which would need repeating. In contrast there
appears to be marked variability in the degree of susceptibility
to MOG-induced disease in C57BL/6 mice. This has occurred
in these experiments, but different disease courses can occur
between and even within the same publications. This variability
seen in disease course could sometimes mean that the
influence of the transgene has as much to do with the disease
incidence and severity of the control group. It is not uncommon
to find weak disease in controls when the transgene or
treatment appears to exacerbate disease, yet control animals
develop strong disease when the transgene or treatment
appears to inhibit disease. This lack of consistency of disease
often gets missed during the review process, but may help
contribute to the dogma about the importance of the
therapeutic target. Line graphs are often used in reporting of
EAE to show the development of disease over time. Low
scores in graphs can mean that animals had lower severity
disease in general or it could mean a low incidence of severe
EAE. Thus, without reporting of incidence of disease, group
sizes and severity and variability the disease induced, as
occurs commonly, this means it is often impossible to interpret
the data [30,32]. This was shown here (Figure 1, Figure 2A) by
way of example and reporting and refereeing standards need
to be improved [32,38].
The data from C57BL/6 background CB2 receptor and
GPR55 knockout mice were used in this study to provide a
concrete example of how the control group could influence the
result, especially as some of the studies in GPR55 knockout
mice were performed at the same time and with the same
batch of immunizing adjuvant as the study in the CB2 knockout
mice. However, vastly different responses were seen in control
groups. The influence of loss of GPR55 protein was supported
in additional experiments in C57BL/6 background mice. The
finding that CB2 receptor knockout can lead to enhanced
disease severity in C57BL-background Cnr2-/- mice [12,13]
was thus consistent in C57BL/6.Cnrttm1Zim and C57BL/
6.Cnr2tm1Dgen mice. However, this enhancing effect was not
noticeable in ABH.Cnr2-/- knockout mice, once the CB2
receptor knockout was generated on a fully EAE-susceptible
genetic background. This may relate to the high severity of
disease that is induced in ABH mice, but the data supports the
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Figure 2.  Genetic Background may influence the development of EAE in CB2 receptor knockout mice.  (A) Female
C57BL/6/J wildtype (black symbols. n= 9) and C57BL/6.Cnr2tm1Dgen CB2 receptor knockout mice (white symbols n=10) were injected
with MOG35-55 peptide in Freunds adjuvant and PTX as co-adjuvant (Table 1B). (B) Male and Female wildtype ABH (black symbols
n= 13) or ABH.Cnr2tm1Dgen (Grey symbols. n=12) CB2 receptor knockout mice were injected with spinal cord homogenate in Freunds
adjuvant on day 0 & 7 (Table 1D). These were injected with vehicle or 25mg/kg i.p. THC daily from day 10 onwards (Table 2B).
Neurological signs were scored daily 0-5 scale. The results represent the mean ± SEM daily scores.
doi: 10.1371/journal.pone.0076907.g002
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Figure 3.  High doses of tetrahydrocannabinol inhibit autoimmunity in EAE via a CB1 receptor-dependent rather than a CB2
receptor-dependent mechanism.  Wildtype (solid symbol) and CB1 receptor (Cnr1tm1Par. White symbol. Table 2A) and CB2
(Cnr2tm1Dgen. Grey symbol. Table 2B) receptor ABH congenic knockout mice were injected with mouse spinal homogenate in
Freunds adjuvant on day 0 and 7. Animals were injected daily i.p. with 20-25mg/kg THC (Diamond symbol) in
ethanol:cremophor:phosphate buffered saline (1:1:18) or vehicle (round symbol) in 0.1ml. The results show the incidence of EAE,
the mean maximal neurological score for the group ± SEM, score of animals that develop clinical EAE ± SEM and the day of onset
of neurological signs. *P<0.05, **P<0.01, ***P<0.001 compared to littermate controls.
doi: 10.1371/journal.pone.0076907.g003
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observation that CB2 receptor agonists or antagonists had no
influence on the development of autoimmunity in ABH mice
[16]. This is perhaps not surprising as it was found that marked
immunosuppression only occurs when cannabimimetic effects
are induced following stimulation of neural CB1 receptors, not
immune cells [12,18]. Whilst weak disease may allow a small
inhibitory effect or augmentation to be seen, when severe
disease is induced, it may mean that any small inhibitory/
stimulatory effect is masked, as occurred here. However, with
such minor differences resulting in a small delay or small
reduction in severity of disease, then the chances of the results
being medically relevant are markedly decreased. Importantly,
the chances of pharmacological inhibition of disease,
translating into human benefit are probably reduced also.
Whilst it has been reported that disease severity was
enhanced in B6.Trpv1-/- and B6.Cnr1-/- mice [10,14], these
effects were not particularly noticeable in congenic ABH.Cnr1
and ABH.Trpv1 knockout mice seen here or reported
previously [9]. CB1 receptor mice poorly tolerate the immune
insult and accumulate nerve damage and residual deficit
following neurological attack. This is consistent with a
neuroprotective role of these molecules and is seen with poor
recovery from attack during EAE [32], rather than an overt
immune-enhancing effect [9,18,32]. Enhanced severity and
poor recovery from EAE has been reported in C57BL/6.Trpv1-/-
[14], but recently it has been reported that B6.Trpv1-/- do not
develop MOG35-55 peptide induced EAE suggesting some
immune influence [39], despite animals being obtained from the
same source and using essentially the same EAE induction
technique. This further highlights the inconsistency of MOG
peptide-induced EAE that can sometimes occur in C57BL/6
mice [14,39]. Furthermore, immunomodulatory influences in
B6.Faah-/- fatty acid amide hydrolase (FAAH) knockout mice
have been suggested by the disease course [10], but have not
been supported by other studies in either B6.Faah-/- [40,41] or
ABH.Faah-/- [41] mice. In both instances, the data suggest that
FAAH may limit neurodegeneration as a consequence of
immune attack, which is consistent with pharmacological
control of disease by exogenous cannabinoids [9,18]. During
EAE in ABH mice the initial attack is driven by an immune-
mediated effect, whereas the relapse additionally contains
demyelination and neurodegenerative effects and it is more
easy to dissociate immunosuppressive verse non-
immunosuppression related neuroprotective effects [16,21,42].
This is more difficult in C57BL/6 mice as EAE is typically
monophasic and is neurodegenerative from onset [10,14,42].
Based on the common findings in these cannabinoid knockout
mice, it is suggests that some of the immune phenotypes seen
in many C57BL/6 knockout studies may likewise become
marginal if the studies were performed in other genetic
backgrounds
In comparison to SJL/J and ABH mice, C57BL/6 mice are
relatively EAE resistant to disease induction with spinal cord
autoantigens and this genetic resistance to disease may
account for variable disease onset [15,16]. Furthermore, this
inconsistency in disease induction may relate also to the use of
MOG35-55 peptide for immunization. MOG35-55 was first found to
induce EAE in Biozzi ABH mice, where it also induces chronic
EAE [30,42]. However the MOG35-55 epitope is a subdominant
compared to MOG8-22 in ABH mice and induces inconsistent
disease incidence, which is sometimes subclinical [30]. In one
experiment, MOG35-55 peptide induced an EAE score of 3.3 ±
0.8 and day of onset 22.8 ± 5.7 (range 16-30 n=5) in ABH
mice, compared to much narrower range of day of onset in
spinal cord induced disease, as shown here. A large range in
timing of disease onset tends to skew the data to incorrectly
appear progressive in nature [32]. Likewise, there are a
number of immunogenic and pathogenic epitopes in MOG for
C57BL/6 mice [43,44]. It has suggested that MOG35-55 may also
be a subdominant encephalitogen in C57BL/6 mice compared
to MOG119-132 [45]. This too may influence the degree of EAE-
susceptibility in C57BL/6 mice as is can in ABH mice [30,42].
To avoid this potential inconsistency we have backcrossed our
C57BL/6 transgenic mice onto the ABH mouse background,
however consistency also may be enhanced through the use of
commercial, quality-controlled adjuvant and adopting standards
for the severity and onset of disease in control groups.
Alternatively, the lack of influence of cannabinoid gene
Table 2. High Dose of tetrahydrocannabinol inhibits autoimmunity in EAE via a CB1 receptor-dependent rather than a CB2
receptor-dependent mechanism.
Code  Strain Treatment  No. EAE Group Score ± SEM EAE Score ± SEM Day of Onset ± SD
A ABH wildtype Vehicle 14/14 3.7 ± 0.1 3.7 ± 0.1 16.2 ± 1.4
 ABH wildtype THC 5/12* 0.5 ± 0.3*** 1.5 ± 0.5** 17.0 ± 0.7
 ABH.Cnr1-/- Vehicle 7/7 3.9 ± 0.1 3.9 ± 0.1 16.3 ± 1.1
 ABH.Cnr1-/- THC 9/9 3.6 ± 0.4 3.6 ± 0.4 17.6 ± 1.7
B ABH wildtype Vehicle 13/13 4.5 ± 0.1 4.5 ± 0.1 15.2 ± 1.3
 ABH wildtype THC 9/12 1.8 ± 0.4*** 2.4 ± 0.3*** 2.4 ± 0.3***
 ABH.Cnr2-/- Vehicle 12/12 4.2 ± 0.2 4.2 ± 0.2 15.5 ± 2.1
 ABH.Cnr2-/- THC 4/13** 0.8 ± 0.4*** 2.5 ± 0.5** 18.8 ± 1.5*
Animals were injected with mouse spinal homogenate in Freunds adjuvant on day 0 and 7. Mice were injected daily i.p. with 20-25mg/kg THC i.p. in
ethanol:cremophor:phosphate buffered saline (1:1:18) in 0.1ml. Animals were monitored from day 11-day 22 post-inoculation. The results show the incidence of EAE, the
mean maximal neurological score for the group ± SEM, score of animals that develop clinical EAE ± SEM and the day of onset of neurological signs. *P<0.05, **P<0.01,
***P<0.001 compared to littermate controls.
doi: 10.1371/journal.pone.0076907.t002
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knockouts in Biozzi ABH mice compared to that found or
reported in EAE in C57BL/6 may relate to the paucity of
polymorphonuclear neutrophils in ABH mouse EAE [16,46] as
occurs in MS [47], compared to more marked neutrophil
involvement in EAE in C57BL/6 mice [48], as occurs in Devics
MS/neuromyelitis optica [47]. Subtle variations in cellular and
humoral immunopathological effector mechanisms between
C57BL/6 and Biozzi ABH mice and the differences induced by
MOG35-55 and spinal cord homogenate probably contribute to
the differences between the two different EAE models [49-51].
This study demonstrated marked differences in the
susceptibility to EAE in different C57BL/6 lines of mice in one
experiment two different control lines showed marked
differences in susceptibility (Table 1A). This may in part relate
to the influences of 129 and C57BL/6 genes to EAE
susceptibility. At the time of testing the wildtype GPR55
knockout line would have had more background 129 genes
than the low-susceptibility CB2 knockout line suggesting that
they may harbour more susceptibility loci or fewer resistant loci,
as 129 mice may be slightly more susceptible than C57BL/6 to
MOG35-55-induced EAE. These genes and copy number can
affect the level of immune response especially if the gene
deletion is located near a susceptibility locus [52,53]. That the
lines gave consistent disease suggests that differences may be
genetic rather than random variation in susceptibility. It is
known there are subtle genetic differences between C57BL/6
sublines [54] and different sublines of mice can sometimes
show differences in susceptibility to EAE [55]. Therefore we
used appropriate littermate controls for these experiments.
However, when backcrossed onto the ABH mouse background
and spinal cord homogenate was used to induce disease there
was much more consistent disease. The low level of
susceptibility in some C57BL/6 mouse experiments suggests
Figure 4.  GPR55-deficiency has marginal effects on the development of EAE in ABH mice.  (A, C) Female and (B, D) male
ABH wildtype (black circles) or ABH.Gpr55-knockout mice (white circles) were injected with spinal cord homogenate in Freunds
adjuvant on day 0 and 7 and a relapse was induced on day 28 post-inoculation. Neurological signs were scored daily 0-5 scale. The
results show the disease course during (A, B) the initial acute or (C, D) an induced relapse. The results represent the mean ± SEM
daily scores. n = 12-21/group.
doi: 10.1371/journal.pone.0076907.g004
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that it is important to set quality control elements in disease
susceptibility when performing such experiments
In the cannabinoid field, few agents are specific for their
target and cannabinoid ligands have variable degrees of
selectively for their receptors [11]. Furthermore agonists and
antagonists can have off-target effects such as SR141617A
which has both an influence on CB1 receptor and GPR55,
whereas other agents such as O-1602 may bind to GPR55 and
GPR18 [3,56]. Therefore, use of gene knockout mice is an
excellent complementary tool to validate potential targets of
therapeutic agents. However, they may not be infallible.
Although in many instances the entire coding gene can be
removed, in other transgenic mice, sections of the gene are
replaced with a neomycin resistance targeting cassette to
functionally inactivate the gene. In the Cnr2tm1Dgen mouse there
is a 391 base pair deletion in the N terminus of Cnr2. In
contrast, the Cnr2tm1Zim mice have the neomycin resistance
cassette inserted into the last 341 nucleotide base pairs of the
C terminal end of the coding Cnr2 exon. They therefore only
lack a portion of the intracellular loop 3, transmembrane
domains 6 and 7, and the carboxy terminus, which is sufficient
to functionally inactivate the CB2 receptor [27]. However, these
mice have an intact N terminus and promoter of the Cnr2 gene
and produce a truncated CB2 receptor message (Nephi Stella.
University of Washington, Seattle, USA, Personal
Communication). This may produce some dysfunctional
protein, as a cytomegalovirus promoter driven construct of the
predicted truncated CB2 gene in Cnr2tm1Zim mice from the N
terminus to the stop codon after the targeting cassette, led to
detectable protein expression in the cytosol, but not the
surface, of transfected HEK293 cells (Ken Mackie and Brady
Atwood. University of Indiana, Bloomington, USA. Personal
communication). That the relaxation effect of (R)3-(5-
dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-
ethyl)benzamide, which does not bind to CB2 receptor was
inhibited in Cnr2tm1Zim but not in Cnr2tm1Dgen mice suggests that
some inhibitory molecule may be indeed generated in this
mouse and possibly interfere with GPR55 function. Whilst the
molecular nature of the precise difference between the strains
is unknown, the pharmacologically different response is
highlighted here, to alert people using these mice. It is
interesting that it has been found that GPR55 can influence
CB2-mediated effects, via “cross-talk” effects on cell signalling
[57]. Therefore, Cnr2tm1Zim mice may functionally influence other
signalling pathways in addition to those of CB2 receptors.
Therefore investigators should be cautious when interpreting
phenotypes using this mouse line, especially as CB2 and
GPR55 may influence similar functions such as bone formation
and neutrophil function [58-60]. For this reason Cnr2tm1Dgen mice
were used to generate congenic Cnr2-deficient mice.
It was evident that there were strain differences in
susceptibility to EAE induction and whilst it is believed that the
differences were related to the genetic deletion, it is recognised
that as the cells used to generate these knockout mice were
chimeras of 129 and C57BL/6 mice, it is therefore likely that
genetic elements of 129 or C57BL/6 mice are in linkage
disequilibrium with the gene silencing cassette, despite
extensive backcrossing. This associated genetics can
sometimes influence or even account for the immune
phenotype [53,54]. Susceptibility to EAE is polygenic [61-66]
and susceptibility loci have been mapped nearCnr1
(chromosome 4. 16cM), Cnr2 (chromosome 4. 68cM), Trpv1
(chromosome 11. 45cM) and Gpr55 (chromosome1 44 cM).
Minor, non-major histocompatibility complex loci influencing
susceptibility and severity of disease have been mapped to
regions including chromosomes 4 and 11 in ABH mice,
although the major genes controlling susceptibility map to
chromosome 7 [62,64]. Both 129 and C57BL/6 are relatively
EAE resistant [67] but the C57BL/10 genetic background,
which is related to C57BL/6 but contains differences on
chromosome 4 amongst others [68], has been used in mapping
studies and has been shown to contain EAE susceptibility and
resistance genes. Major loci are mapped to chromosome 3 and
7 but many others have been identified across the genome of
C57BL background mice [61,63,65,66]. These include loci on
chromosomes 4 and 11 [65] and interestingly an EAE
susceptibility loci in female mice maps to chromosome 1
(70-90cM) in C57BL (C57BL/10.RIII) background mice [66].
Whether this influenced susceptibility in GPR55 knockout mice
is unknown, but must be borne in mind when considering the
data. However, the differences in susceptibility reported
between C57BL/6.Trpv1 are unlikely to relate to genetics as
the animals were from the same source, indicating that
variation in disease induction can occur [14,39]. At the time of
study there were no specific, high affinity GPR55 antagonists
available to confirm the influence on disease course. However
that CB2 receptor agonism and antagonism did not influence
EAE susceptibility in ABH mice [18], whereas CB2 antagonism
augmented disease in C57BL/6 mice [69], the pharmacological
approaches of receptor antagonism are consistent with the
influence of genetic depletion of receptors in both strains
suggesting that the effect is due to the gene targeting and not
adjacent chromosomal regions.
Deletion of cannabinoid receptor genes have not been
associated with a sexually dimorphic effects in EAE, yet it was
apparent that GPR55 deficient female mice may develop less
autoimmunity compared to males and was seen in both
C57BL/6.Gpr55-/- and ABH.Gpr55-/- mice. The molecular
mechanism of this was not found, but no obvious immune T
cell phenotype was detected here. GPR55 may be involved in
macrophage function and antigen-presentation as GPR55 is
reported to influence osteoclast function [59]. However, the
immune influence may be downstream of an influence of sex
hormones between GPR55 knockout and wildtype mice.
Gonadal hormones are known to influence susceptibility to
EAE [70] and previously gender-restricted and sex hormonal
effects have been noted in GPR55-knockout mice [4,60,71].
Although more females develop MS than males [72], studies in
EAE show that this can be a complex relationship with females
sometimes being more susceptible to males and vice versa
[70,73-75]. Likewise other gender and strain hormonal
influences such as differences in calcifediol a vitamin D
prehormone occur between ABH and C57BL/6 mice, which
again could influence immunity as vitamin D response
elements may control a number of susceptibility genes
including MHC expression [76,77]. However, the GPR55-
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mediated effect in female mice was limited in ABH mice. At the
time of these studies there were no high affinity, specific
GPR55 antagonists available to investigate this further. It has
been suggested that cannabidiol may act as a GPR55
antagonist [78], amongst other things, and whilst it has been
reported that cannabidiol can affect EAE in C57BL/6 mice [79],
it has no influence on the autoimmune component of EAE in
ABH mice [12]. In contrast high doses (>2.5mg/kg i.p.) of THC
could cause immunosuppression in wildtype and CB2-deficient
mice but not to any appreciable extent in CB1-deficent mice.
This further supports the CB1-receptor mediated
immunosuppressive effect that we and others identified earlier
previously in ABH and C57BL/6 mice [18,80]. However, we
believe that a T cell immunosuppressive effect of cannabinoids
in mice, notably THC, is probably an artefact of
suprapharmacological/supraphysiological doses of THC that
cause sedative side-effects in animals, which will never be
achieved in humans. Doses that do not cause overt
cannabimimetic signs are not immunosuppressive and do not
inhibit the generation of EAE, in mice, yet can be useful for
symptom control of spasticity that occurs as a consequence of
damage from repeated neurological attacks [7,18]. This is
consistent with the observations that THC had no real influence
on immune function during phase III trials of cannabis and THC
for symptom control [81]. However, whilst cannabinoids in our
opinion may be not be that important for the generation of
relapsing autoimmunity, once generated cannabinoids may
have neuroprotective effects via an action on microglial cells
and nerves to limit the consequences of immune attack,
facilitating better recovery [1,9,10,18,82]. This is in addition to
their proven effects on symptom control both in EAE and MS
[7,8,83]. In conclusion this study shows that the influence of
transgenesis can vary, dependent on a number of factors.
However, one factor that needs to be addressed is ensuring
that there is robust and consistent disease in transgenic/gene
knockout studies to help improve the translational hit rate of
animal studies.
Supporting Information
Figure S1.  GPR55-deficiency has no effect on mitogen or
MOG-induced proliferation in C57BL/6 mice. Female
C56BL/6.Gpr55 knockout (KO) and heterozygous littermates
expressing the wildtype (WT) GPR55 gene were immunized
with MOG35-55 peptide in Freunds adjuvant on day 0 and were
injected with 200ng of B. pertussis toxin on day 0 and 1. L were
collected on day 9 and re-stimulated in vitro with either (A) 1μg
concanavalin A for 48h (B) MOG peptide at concentrations 1μg
or 10μg for 72h (A). A total of 300,000 cells were resuspended
in a final volume of 100 μl of RPMI medium containing 10%
foetal calf serum and plated in 96 well-plates. After 24-48h a
total of 0.5 units of 3H Thymidine (PerkinElmer LAS,
Beaconsfield, Bucks, UK) was added to each well and cells
were incubated during for 24h at 37°C in 5%CO2. Cells were
then harvested (TOMTEC MACH III M CELL HARVESTER 96,
Warwick, UK) and analysed on a counter (Wallac 1450,
Microbeta Plus Liquid Scintillation Counter, Cambridgeshire,
UK).
(PDF)
Figure S2.  GPR55-deficiency has no effect on MOG
proliferation in vivo in C57BL/6 mice. C56BL/6.Gpr55
knockout and wildtype female littermates were immunized with
MOG35-55 peptide in Freunds adjuvant on day 0 and were
injected with 200ng of B. pertussis toxin on day 0 and 1.
Lymphocytes were collected on day 9 and left either
unstimulated or were re-stimulated in vitro with MOG peptide at
a concentrations of 10μg/mg for 72h. n = 3/group. Cells were
incubated with CSFC and the resultant cellular proliferation
assessed using the number of generations by flow cytometry.
Results present the mean + SEM. n=3/group.
(PDF)
Figure S3.  CB2 receptor knockout variants demonstrate
different pharmacological responses to a GPR55
modulator. The vasa deferentia from male C57BL/6 mice and
(A) C57BL/6.Gpr55tm1Tigm or (B) C57BL/6.Cnr1tm1Zim, C57BL/
6.Cnr2tm1Zim, C57BL/6.Cnr2tm1Dgen were electrically stimulated
the contraction responses assessed following addition of
various concentrations of (R)3-(5-dimethylcarbamoyl-pent-1-
enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide the inhibition
assessed. The results represent the mean ± SEM contractions
n=5-6/group.
(PDF)
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